MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Reevaluation in the Cards for FDA

Article-Reevaluation in the Cards for FDA

MD&DI Associate Editor Maria Fontanazza just returned from the Medical Device Regulatory and Compliance Conference at Harvard University. Here is her report: As the pace of medical innovation continues to accelerate, expect some changes from CDRH in the coming months. Scott Gottlieb, deputy commissioner for medical and scientific affairs in the Office of the Commissioner at FDA, said the agency is ready to tackle regulatory, product, and communication challenges. And with the cost of healthcare increasing, FDA needs to take steps to develop a more efficient approach, said Gottlieb.

A broad initiative, complete with a guidance document, to improve CDRHâEUR(TM)s premarket evaluation process could be coming soon. The agency is reevaluating its system for premarket review and will be working harder at monitoring the performance of products after approval. FDA also wants to communicate more effectively with the broader medical community and keep patients more informed about device issues. This includes a new approach to releasing information about recalls.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.